Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + fulvestrant versus alpelisib + fulvestrant in PIK3CA-mutant HR-positive/HER2-negative advanced breast cancer after CDK4/6 inhibitor progression
CTR20231292Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inavolisib, alpelisib, fulvestrant in breast cancer, sponsored by Roche. Started Aug 2023; status: active.
02
Drugs
inavolisibalpelisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231292.